CSL Behring announced that the FDA has approved a 10g (50mL) vial size for Hizentra (immune serum globulin [human]) liquid.
Hizentra is the first and only 20% subcutaneous immunoglobulin therapy indicated as replacement therapy in patients >2 years old with primary immunodeficiency. The new vial size will reduce the number of vials that patients must use when higher doses are required.
Hizentra supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The full mechanism of action in primary immunodeficiency has not been fully elucidated.
The new Hizentra 10g (50mL) vial size will be available in October. Hizentra liquid is already available in 1g (5mL), 2g (10mL), and 4g (20mL) vial sizes.
For more information call (888) 508-6978 or visit Hizentra.com.